Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
Applied BioMath will participate in multiple presentations during the conference. Jamie Nosbisch, PhD, Principal Scientist, at Applied BioMath will present a poster titled, "Using a Semi-Mechanistic Model to Predict Efficacious Dosing Regimens and Optimal Drug Design Properties for a LNP-Delivered mRNA UGT1A1 Replacement Therapy in Crigler-Najjar Syndrome Type 1 Patients" on Monday, October 23rd from 12:30-1:30pm.
Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, who is a member of the scientific programming committee for the Preclinical and Translational Sciences Track will present a poster titled, "A Next Generation Mathematical Model for the In Vitro to Clinical Translation of T-Cell Engagers" on Monday October 23rd from 11:30-12:30pm.
Dr. Hua will also moderate multiple presentations, including:
- Speaker Spotlight: Advances in Predictive Biomarkers for Drug Development on Monday, October 23rd from 2:30-3:30pm
- Keynote: Navigating Project Optimus: Use of Modeling and Simulation to Inform Dosing Strategies in Oncology on Tuesday, October 24th from 1:30-2:30pm
- Keynote: Predictive Drug Discovery Platforms on Wednesday, October 25th from 1:30-2:30pm
- Hot Topic: Understanding Data Needs for AI/ML Approaches During Preclinical Development on Wednesday, October 25th from 3:00-4:00pm
"We are proud to present our science and participate in discussions surrounding the use of modeling and simulation approaches in therapeutic R&D," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
To learn more about Applied BioMath, visit www.appliedbiomath.com.
About Applied BioMath
Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their therapeutic, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic to increase likelihood of clinical concept and proof of mechanism, and decrease late stage attrition rates. For more information about Applied BioMath and its services and software, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.